Middle East Pharmaceutical Industries Company SJSC
SAU:4016
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
Market Cap | P/B | ||||
---|---|---|---|---|---|
SA |
M
|
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
|
2.5B SAR | 8 | |
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -21 763 099 | |
US |
Eli Lilly and Co
NYSE:LLY
|
834.9B USD | 65.2 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4.4T DKK | 44.7 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 583.1 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
350.3B USD | 5 | ||
US |
Merck & Co Inc
NYSE:MRK
|
327.9B USD | 8.1 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
193.9B GBP | 6.6 | ||
CH |
Roche Holding AG
SIX:ROG
|
197.4B CHF | 6.7 | ||
CH |
Novartis AG
SIX:NOVN
|
185.9B CHF | 5.3 | ||
US |
Pfizer Inc
NYSE:PFE
|
156B USD | 1.7 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.